BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection
July 17 (Reuters) - Cloudbreak Pharma Inc 2592.HK:
FDA COMPLETES SAFETY REVIEW OF CBT-358 IND APPLICATION WITH NO OBJECTION
Further company coverage: 2592.HK
